#United States #Anixa Biosciences #San Jose #CAR-T therapy #Breast Cancer Vaccine

Anixa Biosciences Reports Encouraging Clinical Data at Cancer Immunotherapy Symposium

Anixa Biosciences, Inc. recently presented significant advances in its cancer treatment programs at the Frontiers in Cancer Immunotherapy Symposium, hosted by the New York Academy of Sciences. The company, focused on biotechnology for cancer treatment and prevention, showcased the completed Phase 1 trial data for its breast cancer vaccine and ongoing findings from its ovarian cancer CAR-T therapy trial.

Breast Cancer Vaccine Highlights

The breast cancer vaccine, developed in partnership with the renowned Cleveland Clinic, has completed a Phase 1 clinical trial with promising results. Notably, all primary endpoints were successfully met, and immune responses were observed in 74% of participants. This data was presented by Dr. Emily Esakov Rhoades, who emphasized the vaccine's safety and tolerability at maximum doses, suggesting a solid foundation for further development. The vaccine targets human alpha-lactalbumin, a protein expressed in certain breast cancer types, indicating a novel approach in immunizing against the disease without affecting healthy tissue.

Ovarian Cancer CAR-T Therapy Progress

In another presentation, Anixa detailed its CAR-T therapy, named liraltagene autoleucel (or lira-cel), aimed at treating recurrent ovarian cancer. Presented by Dr. Pamela D. Garzone, the update highlighted encouraging survival observations from patients in the ongoing Phase 1 trial. This therapy specifically targets the follicle-stimulating hormone receptor, selectively expressed on ovarian cancer cells, suggesting a tailored approach to cellular treatment.

Strengthening Collaborations

The symposium not only served to present clinical data but also to underline the collaborations with leading institutions like the Cleveland Clinic and Moffitt Cancer Center. Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, stated the importance of showcasing their clinical-stage programs and how these partnerships bolster their research efforts. The company aims to continue advancing its pipeline, contributing significantly to the fight against cancer.

The Future of Cancer Treatment

Anixa's innovative strategies with their breast cancer vaccine and CAR-T therapy highlight a significant turning point in addressing cancer, a disease affecting millions worldwide. By focusing on immunological approaches and leveraging cutting-edge technology, the company is setting a course for potential breakthroughs in treatment options. As it moves forward, Anixa expects to explore further developments, paving the way for new therapeutic avenues in the cancer landscape.

For more details on the presentations and insights, visit Anixa Biosciences' official website.